This section has been provided by the HPA South West.
22.214.171.124 The measles-mumps-rubella vaccine (MMR) is a safe and highly effective vaccine that was introduced in 1988 with a coverage of over 90% between the early 1990s and 1998. However, a fall in uptake was observed from 1997 (down to 81% in 2003/04) as a result of adverse publicity about the vaccine. More recently in 2009/10, the uptake has increased significantly, reaching 89.1%. Within the South West there is wide variation in MMR uptake by
Primary Care Trust (PCT) (Figure 126.96.36.199).
Figure 188.8.131.52 Uptake of MMR vaccination by second birthday by Primary Care Trust in the South West, 2009/10
184.108.40.206 The incidence of mumps has fallen dramatically since the introduction of the MMR vaccine, but in recent years outbreaks of mumps have occurred in the cohort of children born inthe few years before 1984. These children were too old to be offered the MMR vaccine (introduced in 1988) but were susceptible as they had no previous exposure to the virus and therefore did not have natural immunity.
220.127.116.11 More recently, the HPA has observed cases of measles in traveller communities in England. Whilst it is encouraging that coverage of MMR vaccination is increasing, there is still a need for uptake rates to increase further to be confident of avoiding outbreaks.
18.104.22.168 Actions taken and planned to raise uptake include: work with practices with particularly low uptake MMR conferences and training days targeted to health visitors, practice nurses and GPs improvements in information systems in some areas.
22.214.171.124 Strong and urgent efforts are needed to improve uptake of MMR vaccination and exploit all opportunities to vaccinate children of any age who have not received two doses of MMR. In August 2008, the Chief Medical Officer announced the MMR catch up programme to reduce the risk of a measles epidemic in the UK. Research and analysis conducted by the HPA indicated that around 1.9 million school children and 300,000 pre-school children were not completely vaccinated against measles in England. This suggested that the number of susceptible children had now reached a level where measles transmission could be sustained, leading to the potential for an outbreak of between 30,000 and 100,000 cases.
126.96.36.199 The National Human Papilloma Virus (HPV) Vaccination Programme started at the beginning of September 2008. Certain HPV infections can cause cervical cancer, other cancers and genital warts. The national immunisation programme uses the bivalent HPV vaccine (Cervarix TM, GlaxoSmithKline) and will protect girls against infection with HPV 16 and 18 which are associated with 70% of cervical cancers. Annual HPV vaccine uptake data for 2009/10 are presented by PCT in the South West for Year 8 girls aged 12–13 (Cohort 7) in Figure
Figure 188.8.131.52 Uptake of the HPV vaccine in girls 12 - 13 in Primary Care Trusts in the South
West September 2009 - August 2010